Paula Green Sells 291 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 291 shares of the stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $41.68, for a total transaction of $12,128.88. Following the sale, the senior vice president now owns 130,621 shares in the company, valued at approximately $5,444,283.28. This trade represents a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Paula Green also recently made the following trade(s):

• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total value of $37,555.38.
• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total value of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $7,294.40.

Twist Bioscience Trading Down 1.5 %

Shares of TWST stock opened at $44.25 on Wednesday. The stock has a 50-day simple moving average of $45.45 and a 200 day simple moving average of $45.36. The stock has a market capitalization of $2.64 billion, a P/E ratio of -13.09 and a beta of 2.15. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the prior year, the firm earned ($0.75) EPS. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. On average, sell-side analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC purchased a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $56,984,000. Marshall Wace LLP lifted its holdings in shares of Twist Bioscience by 15,927.8% in the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company’s stock valued at $39,319,000 after purchasing an additional 840,828 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after buying an additional 532,040 shares during the period. State Street Corp raised its position in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after buying an additional 526,028 shares during the period. Finally, Wellington Management Group LLP lifted its stake in Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after acquiring an additional 521,272 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently weighed in on TWST. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.